Resverlogix Corp. (TSE:RVX – Get Free Report)’s stock price hit a new 52-week low during trading on Thursday. The company traded as low as C$0.09 and last traded at C$0.09, with a volume of 23,300 shares traded. The stock had previously closed at C$0.08.
Resverlogix Stock Performance
The company has a market capitalization of C$30.99 million, a P/E ratio of -2.25 and a beta of -0.11. The company has a debt-to-equity ratio of -82.47, a current ratio of 0.04 and a quick ratio of 0.04. The stock’s 50 day simple moving average is C$0.09 and its two-hundred day simple moving average is C$0.10.
Resverlogix Company Profile
Founded in 2001, Resverlogix is a Calgary based late-stage biotechnology company, and a world leader in epigenetics, with the goal of developing first-in-class therapies for the benefit of patients with chronic disease. Resverlogix is developing a new class of epigenetic therapies designed to regulate the expression of disease-causing genes. We aim to improve patients’ lives by restoring biological functions – altered by serious illnesses such as cardiovascular disease – back to a healthier state.
Further Reading
- Five stocks we like better than Resverlogix
- Bloom Energy Just Reported—Its Biggest Order Is Still Waiting on a Pipeline
- Why Western Digital’s AI Storage Boom Defies the Chip Sell-Off
- Grand Canyon Education Strengthens Its Outlook, But Wall Street Remains Divided
- Amex Stock Slides on Job Cuts, But the Real Story Is Macro
Receive News & Ratings for Resverlogix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Resverlogix and related companies with MarketBeat.com's FREE daily email newsletter.
